SecBot SecBot
SECBOTREPLAY Home › Report › ADCT

ADCT · PIPE resale S-3 filed

ADC Therapeutics SA · S-3 filed Nov 9, 2026 at 18:39 ET

At the news

NEUTRALIMPACT 3/10

S-3 filed Nov 9, 2026 at 18:39 ET

ADC Therapeutics filed an S-3 registration statement to register 61,000,000 common shares for resale by investors who participated in the October 2026 $86.6M PIPE. The company will not receive proceeds from share sales but may receive up to CHF 3.8M if pre-funded warrants are exercised for cash. This filing is a routine contractual obligation from the PIPE, not a new offering, and follows the company's recent debt restructuring and Q3 revenue growth.

  • S-3 registers 61,000,000 common shares for resale by selling shareholders from the October 2026 PIPE
  • Includes 12,911,347 common shares and 48,088,653 shares issuable upon exercise of pre-funded warrants
  • Company will not receive proceeds from share sales; may receive up to CHF 3,847,092 if pre-funded warrants exercised for cash
  • PIPE raised $86.6M at $1.42 per share and $1.324 per pre-funded warrant, closed October 22, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access